Patents by Inventor Morten Lundh

Morten Lundh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HAManalogues with improved amylin receptor (hAMY3R) potency
    Patent number: 12139520
    Abstract: The present invention relates to hAM15-52 analogues with improved amylin receptor (hAMY3R) potency (hAMY3R-EC50?250 pM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The invention further relates to hAM15-52 analogues that are selective amylin receptor (hAMY3R) agonists (hAMY3R-EC50?250 pM and an hAM1R-EC50?25 nM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The hAM15-52 analogues according to the invention maintain the good physical stability of hAM15-52. The invention further relates to pharmaceutical compositions comprising such polypeptides and their use in the treatment of a medical condition such as obesity, NASH and/or diabetes.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: November 12, 2024
    Assignee: GUBRA A/S
    Inventors: Jens Christian Frøslev Nielsen, Kristoffer Tobias Gustav Rigbolt, Esben Matzen Bech, Morten Lundh, Paola Magotti, Borja Ballarín-González, Søren Ljungberg Pedersen, Niels Vrang
  • hAM15-52 ANALOGUES WITH IMPROVED AMYLIN RECEPTOR (hAMY3R) POTENCY
    Publication number: 20240101634
    Abstract: The present invention relates to hAM15-52 analogues with improved amylin receptor (hAMY3R) potency (hAMY3R-EC50?250 pM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The invention further relates to hAM15-52 analogues that are selective amylin receptor (hAMY3R) agonists (hAMY3R-EC50?250 pM and an hAM1R-EC50?25 nM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The hAM15-52 analogues according to the invention maintain the good physical stability of hAM15-52. The invention further relates to pharmaceutical compositions comprising such polypeptides and their use in the treatment of a medical condition such as obesity, NASH and/or diabetes.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 28, 2024
    Applicant: GUBRA A/S
    Inventors: Jens Christian Frøslev NIELSEN, Kristoffer Tobias, Gustav RIGBOLT, Esben Matzen BECH, Morten LUNDH, Paola MAGOTTI, Borja BALLARiN-GONZÁLEZ, Søren Ljungberg PEDERSEN, Nieis VRANG
  • Inhibitors of histone deacetylase
    Patent number: 11377423
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: July 5, 2022
    Assignees: The Broad Institute, Inc., The General Hospital Corporation
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
  • INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20180072671
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistence. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Application
    Filed: August 16, 2017
    Publication date: March 15, 2018
    Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
  • Inhibitors of histone deacetylase
    Patent number: 9790184
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: October 17, 2017
    Assignees: The Broad Institute, Inc., The General Hospital Corporation
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
  • INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20150191427
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Application
    Filed: July 29, 2013
    Publication date: July 9, 2015
    Applicants: The General Hospital Corporation d/b/a Massachusetts General Hospital, The Broad Institute, Inc.
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis